Preliminary Evidence of Efficacy and Target Engagement of Pramipexole in Anhedonic Depression.

ABSTRACT:

Objective

To investigate feasibility and target engagement of high-dose, add-on pramipexole treatment in anhedonic depression.

Method

In this open-label pilot study, we included 12 patients with unipolar or bipolar, moderate-to-severe depression and with significant anhedonia symptoms. All patients were on a stable dose of one or a combination of antidepressants and/or mood stabilizers and received 10 weeks of adjunctive pramipexole titrated to a maximum dose of 4.5 mg salt/day. All patients were rated with the Dimensional Anhedonia Rating Scale (DARS), the Montgomery Åsberg Depression Rating (MADRS) and the Snaith Hamilton Pleasure Scale (SHAPS). Serum high-sensitivity C-reactive protein (hs-CRP) was analyzed pre- and post-treatment. Eight patients underwent fMRI pre- and p

SUBMITTER: Ventorp F 

PROVIDER: S-EPMC9534553 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature